EGFR and non-small cell lung carcinoma: Studies conducted using the H596 NSCLC xenograft model have indicated that combining ficlatuzumab with epidermal growth factor receptor (EGFR) inhibitors such as erlotinib or cetuximab enhances its anti-cancer effects compared to using either agent alone.